Summit Therapeutics (SMMT) Assets Average (2020 - 2025)
Summit Therapeutics' Assets Average history spans 6 years, with the latest figure at $177.9 million for Q4 2025.
- For Q4 2025, Assets Average fell 62.09% year-over-year to $177.9 million; the TTM value through Dec 2025 reached $177.9 million, down 62.09%, while the annual FY2024 figure was $319.3 million, 26.36% down from the prior year.
- Assets Average reached $177.9 million in Q4 2025 per SMMT's latest filing, down from $292.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $469.2 million in Q4 2024 to a low of $106.1 million in Q2 2022.
- Average Assets Average over 5 years is $249.9 million, with a median of $219.3 million recorded in 2023.
- Peak YoY movement for Assets Average: soared 299.86% in 2023, then tumbled 62.09% in 2025.
- A 5-year view of Assets Average shows it stood at $121.0 million in 2021, then surged by 238.57% to $409.7 million in 2022, then plummeted by 48.58% to $210.7 million in 2023, then soared by 122.68% to $469.2 million in 2024, then crashed by 62.09% to $177.9 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Assets Average are $177.9 million (Q4 2025), $292.9 million (Q3 2025), and $353.9 million (Q2 2025).